Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Average Target - Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Evolution of the Target Price - Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

5fd0dbb8e7beb9380d2a4be6.V6RDXnB9sv0E7yp-Swb3N37bKuND_JjKDHaYCwVcEpI.Mu8uFygFxpRQpRsYfDOfYy2cdbApy9GMQSGpRHIqVvgV9HMwGifEz2mHew~08c9243633df637b16bf82e1fcd68547
Oct. 21 Gilead's Biktarvy Pricing Impact Likely Manageable, RBC Says MT
Oct. 15 Goldman Sachs Adjusts Price Target on Gilead Sciences to $142 From $135 MT
Oct. 12 Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says MT
Oct. 12 BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating MT
Oct. 08 RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating MT
Oct. 07 Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165 MT
Oct. 07 JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160 MT
Oct. 02 Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says MT
Sep. 10 HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating MT
Aug. 05 Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says MT
Aug. 05 Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126 MT
Aug. 05 Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130 MT
Aug. 05 RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating MT
Aug. 04 Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says MT
Jul. 28 Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating MT
Jul. 23 Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating MT
Jul. 21 Gilead Sciences Shares Fall After Downgrade From Leerink Partners MT
Jul. 21 Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike… Zonebourse
Jul. 21 Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146 MT
Jul. 08 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
Jul. 08 Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating MT
Jul. 07 Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 MT
Jul. 07 RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating MT
Jul. 06 Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow… Zonebourse
Jul. 06 HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+1.89%
+1.9%
+4.41%
-0.14%
-1.64%
+7.69%
-4.18%
+21.09%
-11.31%
+12.59%
Average +3.23%
Weighted average by Cap. +2.71%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
157.19USD
Average target price
159.20USD
Spread / Average Target
+1.28%
High Price Target
177.00USD
Spread / Highest target
+12.60%
Low Price Target
126.00USD
Spread / Lowest Target
-19.84%

Analyst Consensus Detail

Analyst consensus - Gilead Sciences, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Gilead Sciences, Inc.
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Gilead Sciences, Inc.
  1. Stock Market
  2. Stocks
  3. GILD Stock
  4. Consensus Gilead Sciences, Inc.